200 related articles for article (PubMed ID: 33015538)
1. Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites.
Pillai M; Davies MM; Thistlethwaite FC
Ther Adv Vaccines Immunother; 2020; 8():2515135520944355. PubMed ID: 33015538
[TBL] [Abstract][Full Text] [Related]
2. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
[TBL] [Abstract][Full Text] [Related]
3. Advanced therapy medicinal products: current and future perspectives.
Hanna E; Rémuzat C; Auquier P; Toumi M
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
[TBL] [Abstract][Full Text] [Related]
4. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine.
Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A
J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311
[TBL] [Abstract][Full Text] [Related]
5. Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease.
Woods N; MacLoughlin R
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32993197
[TBL] [Abstract][Full Text] [Related]
6. Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials.
Hanna E; Rémuzat C; Auquier P; Toumi M
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27570614
[TBL] [Abstract][Full Text] [Related]
7. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework.
López-Paniagua M; de la Mata A; Galindo S; Blázquez F; Calonge M; Nieto-Miguel T
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800934
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of institutional readiness at sites within the UK NHS using a novel advanced therapy medicinal product assessment tool.
Wotherspoon L; Buchan R; Morrison E; Amatt G
Regen Med; 2021 Mar; 16(3):253-268. PubMed ID: 33724873
[TBL] [Abstract][Full Text] [Related]
9. Surgery Versus ATMPs: An Example From Ophthalmology.
Magrelli FM; Merra A; Pellegrini G
Front Bioeng Biotechnol; 2020; 8():440. PubMed ID: 32587848
[TBL] [Abstract][Full Text] [Related]
10. Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe.
Ten Ham RMT; Hoekman J; Hövels AM; Broekmans AW; Leufkens HGM; Klungel OH
Mol Ther Methods Clin Dev; 2018 Dec; 11():121-130. PubMed ID: 30456217
[TBL] [Abstract][Full Text] [Related]
11. The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time.
Piemonti L; Scholz H; de Jongh D; Kerr-Conte J; van Apeldoorn A; Shaw JAM; Engelse MA; Bunnik E; Mühlemann M; Pal-Kutas K; Scott WE; Magalon J; Kugelmeier P; Berishvili E
Transpl Int; 2023; 36():11633. PubMed ID: 37822447
[TBL] [Abstract][Full Text] [Related]
12. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
13. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
14. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation.
Detela G; Lodge A
Mol Ther Methods Clin Dev; 2019 Jun; 13():205-232. PubMed ID: 30815512
[TBL] [Abstract][Full Text] [Related]
15. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
[TBL] [Abstract][Full Text] [Related]
16. European regulatory tools for advanced therapy medicinal products.
Flory E; Reinhardt J
Transfus Med Hemother; 2013 Dec; 40(6):409-12. PubMed ID: 24474890
[TBL] [Abstract][Full Text] [Related]
17. Advanced Therapy Medicinal Products and the Changing Role of Academia.
Priesner C; Hildebrandt M
Transfus Med Hemother; 2022 Jun; 49(3):158-162. PubMed ID: 35813600
[TBL] [Abstract][Full Text] [Related]
18. Advanced therapy medicinal products in China: Regulation and development.
Lu J; Xu L; Wei W; He W
MedComm (2020); 2023 Jun; 4(3):e251. PubMed ID: 37125239
[TBL] [Abstract][Full Text] [Related]
19. Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?
Seimetz D; Heller K; Richter J
Cell Med; 2019; 11():2155179018822781. PubMed ID: 32634192
[TBL] [Abstract][Full Text] [Related]
20. ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.
Damerval M; Fagnoni-Legat C; Louvrier A; Fischer S; Limat S; Clairet AL; Nerich V; Madelaine I; Kroemer M
Front Med (Lausanne); 2021; 8():713047. PubMed ID: 34926483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]